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Abstract
The hitherto unknown 2,6-hexadecadiynoic acid, 2,6-nonadecadiynoic acid, and 2,9-
hexadecadiynoic acid were synthesized in two steps and in 11–18% overall yields starting from either
1,5-hexadiyne or 1,8-nonadiyne. Among all the compounds 2,6-hexadecadiynoic acid displayed the
best overall antifungal activity against both the fluconazole resistant Candida albicans strains ATCC
14053 and ATCC 60193 (MIC = 11 μM) and against Cryptococcus neoformans ATCC 66031 (MIC
< 5.7 μM). The 2,9-hexadecadiynoic acid did not display any significant cytotoxicity against the
fluconazole resistant C. albicans strains, but it showed fungitoxicity against C. neoformans ATCC
66031 with a MIC value of <5.8 μM. Other fatty acids, such as 2-hexadecynoic acid, 5-hexadecynoic
acid, 9-hexadecynoic acid, and 6-nonadecynoic acid were also synthesized and their antifungal
activities compared. The 2-hexadecynoic acid, a known antifungal fatty acid, exhibited the best
antifungal activity (MIC = 9.4 μM) against the fluconazole resistant C. albicans ATCC 14053 strain,
but it showed a MIC value of only 100 μM against C. albicans ATCC 60193. The fatty acids 2,6-
hexadecadiynoic acid and 2-hexadecynoic acid also displayed a MIC of 140–145 μM towards
Mycobacterium tuberculosis H37Rv in Middlebrook 7H12 medium. In conclusion, 2,6-
hexadecadiynoic acid exhibited the best fungitoxicity profile compared to other analogues. This
diynoic fatty acid has the potential to be further evaluated for use in topical antifungal formulations.
The 2-alkynoic fatty acids (FA) have been known to be fungitoxic (1–2). The fungal activity
of these compounds depends on the FA chain length and pH of the medium (1–2). The optimal
chain lengths between 8 and 16 carbons have been established for the 2-alkynoic FA to exert
maximum fungistatic effects (2). Among the 2-alkynoic FA the 2-hexadecynoic acid has
received the most attention for its antifungal, antimicrobial, and cytotoxic properties (3–5).
The bioactivity of the 2-hexadecynoic acid has been ascribed to its ability to inhibit the
elongation of saturated and unsaturated FA as well as its potential to inhibit the FA acylation
process, particularly triglyceride synthesis (4–5).
Other isomeric alkynoic FA, in particular the 6-alkynoic FA, are also fungistatic. For example,
when an unsaturation is introduced between C-6 and C-7 in a fatty acyl chain the FA displays
good fungitoxicity. It is shown that 6-hexadecynoic acid is a good substrate for the enzyme
myristoyl-CoA:protein N-myristoyltransferase from Saccharomyces cerevisiae, an important
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enzyme for fungal growth and a good target for antifungal therapy (6). Furthermore, 6-
nonadecynoic acid, recently isolated from the roots of Pentagonia gigantifolia, is reported to
be fungistatic against some fungal strains of fluconazole resistant Candida albicans (7) as well
as to Cryptococcus neoformans (8). C. albicans and C. neoformans are pathogenic fungi of
concern in immunocompromised patients. On the other hand, 6-alkenoic FA have been also
evaluated. For example, the 6-hexadecenoic acid is antimicrobial to gram-positive bacteria
(MIC’s of 10–20 μg/ml) and blocks the adherence of C. albicans to porcine stratum corneum
(9).
With this information at hand regarding the antifungal activities of 2-alkynoic and 6-alkynoic
FA, we envisaged the possibility of combining in a single molecule the C-2 and C-6 ynoic
functionalities, i.e., by synthesizing 2,6-diynoic FA and evaluating their antifungal properties.
It was expected that novel 2,6-diynoic FA to have a better antifungal profile than either of the
parent 2-alkynoic or 6-alkynoic FA. The synthesis of 2,6-octadecadiynoic acid as a precursor
to furan-containing FA has been previously reported by Lie Ken Jie et. al. (10–11). However,
to the best of our knowledge, the FA 2,6-hexadecadiynoic acid (3a) and 2,6-nonadecadiynoic
acid (3c) are novel. We describe the synthesis of the dimethylene-interrupted diynoic FA 3a
and 3c, as well as the synthesis of the 2,9-hexadecadiynoic acid (3b). Comparative antifungal
activities of the compounds indicated that 3a had the best fungitoxicity profile among the
studied compounds and the known 2-hexadecynoic acid.
MATERIALS AND METHODS
Instrumentation
1H and 13C NMR spectra were recorded on either a Bruker DPX-300 or a Bruker DRX-500
spectrometer. 1H NMR chemical shifts are reported with respect to internal Me4Si and chemical
shifts are given in parts per million (ppm) relative to CDCl3 (77.0 ppm). Mass spectral data
was acquired on a GC-MS (Hewlett-Packard 5972A MS ChemStation) instrument at 70 eV,
equipped with a 30 m x 0.25 mm special performance capillary column (HP-5MS) of
polymethylsiloxane cross-linked with 5% phenyl methylpolysiloxane. Infrared spectra were
recorded on a Nicolet 600 FT-IR spectrophotometer.
Microorganisms
C. albicans ATCC 60193, C. albicans ATCC 14053, and C. neoformans ATCC 66031 were
obtained from American Type Culture Collection, Manassas, Virginia, USA. Stock cultures
were kept on Sabouraud Dextrose Agar (SDA; Becton-Dickinson and Co., Sparks, Maryland).
Subcultures were prepared on SDA at 35–37°C. Suspension cultures were prepared by
inoculation of single colonies in 7 ml of normal saline solution. Prior to preparation of
susceptibility assays, yeast cells were resuspended in normal saline to make a transmittance of
73–75% at 530 nm that provide equivalent concentration of 106 cells/ml. The media was
Sabourand dextrose broth (SDB; Becton Dickinson and Co., Sparks, Maryland).
Chemicals and Antifungal Agents
Amphotericin B (AMB) was purchased from Acros, New Jersey, USA, and was kept as a 5
mM stock in DMSO at 0°C and used during one week of preparation. Fluconazole (FLC) was
purchased from Medisa Inc., New York, NY, USA, or was provided from Vera Laboratories
Ltd, Hyderabad, India, and was kept as a 20 mM stock solution at 0°C. Working dilutions were
made in SDB medium. Higher concentrations of compounds were used for those with weak
antifungal activities. The final maximum concentration of DMSO in the assays was 5% (v/v).
DMSO was not inhibitory to the organisms tested.
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Susceptibility Testing
Microdilutions for control experiments with C. albicans and C. neoformans were performed
according to the modified method of National Committee for Clinical Laboratory Standards
(NCCLS) method as described by Galgiani (12) and according to the more recent NCCLS
M27-A microdilution methods as described previously (13–14). Dilutions were prepared in
0.1 ml of SDB; the inocula were either 104 C. albicans or C. neoformans cells. The tubes were
incubated for 24–48 h at 36 ± 1°C, and turbidity was read visually. MICs were calculated in
comparison to growth control as the lowest concentration that shows inhibition for AMB, FLC,
and the test compounds.
General procedure for the mono-alkylation of the diynes
To a stirred solution of the diyne (8.3–12.8 mmol) in dry THF (20–25 mL), n-Buli (2.5 M, 7.5–
11.5 mmol) in dry hexane (3.0–5.0 mL) was added drop wise while keeping the temperature
at −78°C. After 45 min, HMPA (3.0–5.0 mL) and the bromoalkane (7.7–11.5 mmol) were
added drop wise to the reaction mixture while maintaining the temperature at −78°C. After 24
h, the reaction mixture was worked up by pouring into a large volume of water, and extracting
with diethyl ether (2 x 20 mL). The organic layer was washed with brine (1 x 20 mL) before
drying (MgSO4). Filtration, rotoevaporation of the solvent, and fractional distillation afforded
the mono-alkylated diynes 2a-2c in 21–47 % yields after purification by Kugel-Rohr
distillation (60–100°C/3 mm Hg) of the impurities.
a. 1,8-Pentadecadiyne (2b) was obtained in a 21% yield as a viscous oil from the reaction
of 1.22 mL of 1,8-nonadiyne (1.00 g, 8.32 mmol) and 1.16 mL of 1-bromohexane
(1.37 g, 8.32 mmol) according to the general procedure described above. IR (neat)
νmax 3311, 2932, 2859, 2118, 1463, 1332, 1192, 1100, 629 cm−1; 1H-NMR (CDCl3,
500 MHz) δ 2.19 (2H, dt, J = 2.6 and 6.9 Hz, H-10), 2.13 (4H, m, H-3, H-7), 1.93
(1H, t, J = 2.6 Hz, H-1), 1.57-1.24 (14H, m, -CH2-), 0.88 (3H, t, J = 7.0 Hz,
H-15); 13C-NMR (CDCl3, 125 MHz) δ 84.53 (s, C-2), 80.48 (s), 79.84 (s), 68.15 (d,
C-1), 31.36 (t, C-13), 29.10 (t), 28.61 (t), 28.53 (t), 28.04 (t), 27.95 (t), 22.56 (t, C-14),
18.73 (t), 18.69 (t), 18.33 (t), 14.04 (q, C-15); GC-MS m/z (relative intensity) M+ 204
(0.1), 189 (1), 175 (4), 161 (4), 147 (14), 133 (28), 119 (32), 107 (11), 105 (54), 95
(13), 91 (C7H7+, 100), 81 (30), 79 (61), 67 (51), 55 (31).
(ii) 1,5-Pentadecadiyne (2a) was obtained in a 40% yield as a viscous oil from the
reaction of 2.5 mL of 1,5-hexadiyne (1.00 g, 12.80 mmol) and 2.2 mL of 1-
bromononane (2.38 g, 11.50 mmol) according to the general procedure described
above. IR (neat) νmax 3313, 2926, 2855, 2122, 1466, 1338, 1257, 635 cm−1; 1H-NMR
(CDCl3, 500 MHz) δ 2.38 (4H, m, H-3, H-4), 2.14 (2H, brt, J = 7.0 Hz, H-7), 2.00
(1H, t, J = 2.0 Hz, H-1), 1.52-1.27 (14H, m, -CH2-), 0.88 (3H, t, J = 6.9 Hz,
H-15); 13C-NMR (CDCl3, 125 MHz) δ 83.11 (s, C-2), 81.61 (s), 78.09 (s), 68.94 (d,
C-1), 31.89 (t, C-13), 29.50 (t), 29.28 (t), 29.16 (t), 28.97 (t), 28.83 (t), 22.67 (t, C-14),
19.18 (t), 18.93 (t), 18.71 (t), 14.09 (q, C-15); GC-MS m/z (relative intensity) M+ 204
(0.1), 161 (1), 147 (3), 133 (13), 119 (19), 109 (6), 105 (31), 95 (16), 91 (C7H7+, 100),
81 (22), 79 (31), 67 (32), 65 (20), 55 (29).
(iii) 1,5-Octadecadiyne (2c) was obtained as a viscous oil in a 47% yield from the
reaction of 2.5 mL of 1,5-hexadiyne (2.00 g, 12.80 mmol) and 1.8 mL of 1-
bromododecane (1.87 g, 7.70 mmol) according to the general procedure described
above. IR (neat) νmax 3313, 2925, 2854, 2122, 1466, 1338, 1257, 635 cm−1; 1H-NMR
(CDCl3, 500 MHz) δ 2.38 (4H, m, H-3, H-4), 2.14 (2H, brt, J = 6.9 Hz, H-7), 2.00
(1H, m, H-1), 1.55-1.26 (20H, m, -CH2-), 0.88 (3H, t, J = 6.8 Hz, H-18); 13C-NMR
(CDCl3, 125 MHz) δ 83.11 (s, C-2), 81.62 (s), 78.09 (s), 68.93 (d, C-1), 31.92 (t,
C-16), 29.67 (t), 29.64 (t), 29.63 (t), 29.55 (t), 29.35 (t), 29.16 (t), 28.97 (t), 28.83
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(t), 22.68 (t, C-17), 19.18 (t), 18.93 (t), 18.71 (t), 14.10 (q, C-18); GC-MS m/z (relative
intensity) M+ 246 (0.1), 175 (1), 161 (2), 147 (8), 133 (27), 119 (27), 105 (38), 95
(16), 91 (C7H7+, 100), 81 (20), 79 (35), 67 (28), 65 (24), 55 (29).
General procedure for the carboxylation of the alkylated diynes
To a stirred solution of the alkylated diynes (2a-2c, 1.7–4.6 mmol) in dry THF (17–46 mL),
n-Buli (2.5 M, 2.6–7.2 mmol) in dry hexane (1–3 mL) was added drop wise while keeping the
temperature approximately at −78°C. After 45 min the reaction mixture was treated with dry
CO2 (by passing the CO2 through sulfuric acid) and left stirring for 24 h. The reaction mixture
was then worked up by pouring into a large volume of a saturated solution of ammonium
chloride followed by extraction with diethyl ether (3 x 20 mL). Rotoevaporation of the solvent
afforded the diynoic acids 3a-3c in 28–52% yields after purification by Kugel-Rohr distillation
(60–100°C/3 mm Hg) of the impurities. The higher yield (52%) was obtained for 2,9-
hexadecadiynoic acid (3b).
a. 2,9-Hexadecadiynoic acid (3b) was obtained as an oil in a 52% yield from the reaction
of 1,8-pentadecadiyne (0.35 g, 1.70 mmol) and excess dry CO2 (by passing the
CO2 through sulfuric acid) according to the general procedure described above. IR
(neat) νmax 3400-2900 (br), 2932, 2859, 2238, 1688, 1462, 1410, 1332, 1279, 1076
cm−1; 1H-NMR (CDCl3, 500 MHz) δ 2.36 (2H, t, J = 7.1 Hz, H-4), 2.14 (4H, m, H-8,
H-11), 1.62-1.23 (14H, m, -CH2-), 0.88 (3H, t, J = 7.0 Hz, H-16); 13C-NMR
(CDCl3,125 MHz) δ 157.08 (s, C-1), 92.01 (s, C-3), 81.24 (s), 80.71 (s), 72.69 (s,
C-2), 31.35 (t, C-14), 29.08 (t), 28.54 (t), 28.43 (t), 27.96 (t), 26.98 (t), 22.56 (t, C-15),
18.72 (t), 18.69 (t), 18.55 (t), 14.04 (q, C-16).
(ii) 2,6-Hexadecadiynoic acid (3a) was obtained as a white solid in a 45% yield from
the reaction of 1,5-pentadecadiyne (0.94 g, 4.60 mmol) and excess dry CO2 (by
passing the CO2 through sulfuric acid) according to the general procedure described
above. M. p. 48-50°C, IR (neat) νmax 3400-2900 (br), 2953, 2915, 2848, 2246, 1674,
1469, 1425, 1300, 1276, 1075, 890, 608 cm−1; 1H-NMR (CDCl3, 500 MHz,) δ 2.54
(2H, brt, J = 7.3 Hz, H-4), 2.44 (2H, m, H-5), 2.14 (2H, tt, J = 2.2 and 7.1 Hz, H-8),
1.47 (2H, m, H-9), 1.40-1.27 (12H, m, -CH2-), 0.88 (3H, t, J = 6.9 Hz, H-16); 13C-
NMR (CDCl3, 125 MHz) δ 156.58 (s, C-1), 90.10 (s, C-3), 82.44 (s), 77.10 (s), 73.14
(s, C-2), 31.83 (t, C-14), 29.48 (t), 29.29 (t), 29.15 (t), 28.86 (t), 28.83 (t), 22.67 (t,
C-15), 19.51 (t, C-4), 18.67 (t, C-8), 17.94 (t, C-5), 14.08 (q, C-16). Anal. calcd. for
C16H24O2: C, 77.38; H, 9.74. Found: C, 76.17; H, 10.19.
(iii) 2,6-Nonadecadiynoic acid (3c) was obtained as a white solid in a 28% yield from
the reaction of 1,5-octadecadiyne (0.89 g, 3.60 mmol) and excess dry CO2 (by
bubbling the CO2 through sulfuric acid) according to the general procedure described
above. M. p. 62-64°C, IR (neat) νmax 3400-2900 (br), 2953, 2916, 2848, 2245, 1671,
1422, 1280, 912, 720 cm−1; 1H-NMR (CDCl3, 500 MHz) δ 2.54 (2H, brt, J = 7.4 Hz,
H-4), 2.44 (2H, m, H-5), 2.14 (2H, tt, J = 2.3 and 7.1 Hz, H-8), 1.47 (2H, m, H-9),
1.38-1.25 (18H, m, -CH2-), 0.88 (3H, t, J = 6.9 Hz, H-19); 13C-NMR (CDCl3, 75
MHz) δ 156.96 (s, C-1), 90.33 (s, C-3), 82.44 (s), 77.21 (s), 73.06 (s, C-2), 31.91 (t,
C-17), 29.64 (t), 29.53 (t), 29.35 (t), 29.14 (t), 28.84 (t), 22.68 (t, C-18), 19.49 (t, C-4),
18.66 (t, C-8), 17.91 (t, C-5), 14.11 (q, C-19). Anal. calcd. for C19H30O2: C, 78.57;
H, 10.41. Found: C, 77.14; H, 10.40.
RESULTS AND DISCUSSION
Seven acetylenic fatty acids were synthesized and evaluated for antifungal activities against
C. albicans and C. neoformans. The acetylenic fatty acids 2-hexadecynoic acid, 5-
hexadecynoic acid, 9-hexadecynoic acid, and 6-nonadecynoic acid were synthesized according
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to the previously described procedures (1,8,15). Despite the fact that the 2,6-octadecadiynoic
acid has been previously synthesized (10–11), there are no reported syntheses for acids
3a-3c. Therefore, a simple synthetic methodology for the preparation of novel fatty acids
3a-3c was developed based on two consecutive acetylide coupling reactions.
The synthesis of the dimethylene-interrupted 2,6-hexadecadiynoic acid (3a) and 2,6-
nonadecadiynoic acid (3c) was conveniently accomplished using 1,5-hexadiyne (50% in
pentane) as the starting material (Scheme 1). In the preparation of 3a, 1,5-hexadiyne was
coupled with 1-bromononane using n-BuLi in THF/HMPA at −78°C, which afforded 1,5-
pentadecadiyne (2a) in a 40% yield. Likewise, for the synthesis of acid 3c, the 1,5-hexadiyne
was coupled with 1-bromododecane using the above mentioned acetylide coupling conditions,
which afforded 1,5-octadecadiyne (2c) in a 47% yield after final purification (Scheme 1).
Coupling of the lithium acetylides of 1,5-pentadecadiyne (2a) or the 1,5-octadecadiyne (2c)
with carbon dioxide and subsequent protonation with ammonium chloride afforded the 2,6-
hexadecadiynoic acid (3a) or the 2,6-nonadecadiynoic acid (3c) in 28–45 % yields after final
purification (Scheme 1). The overall yields for these two two-step syntheses ranged between
13 and 18%.
The preparation of 2,9-hexadecadiynoic acid (3b) followed a similar synthetic strategy, with
the exception that this synthesis started with the 1,8-nonadiyne. The diyne was coupled with
1-bromohexane using again n-BuLi in THF/HMPA at −78°C, which afforded 1,8-
pentadecadiyne (2b) in a 21 % yield after final purification. Final coupling of the lithium
acetylide of 1,8-pentadecadiyne (2b) with carbon dioxide and subsequent protonation with
ammonium chloride afforded the desired 2,9-hexadecadiynoic acid (3b) in a 52 % yield after
final purification (Scheme 1). The overall yield for this two-step synthesis was 11 %.
The antifungal activity of the synthesized acetylenic fatty acids against Candida albicans
strains ATCC 14053 and ATCC 60193, and Cryptococcus neoformans ATCC 66031 in SDB
media were determined using a modified method of the National Committee for Clinical
Laboratory Standards (NCCLS) as described by Galgiani and the more recent NCCLS M27-
A microdilution methods as described previously (12–13) (Table 1). Amphotericin B (AMB)
and fluconazole (FLC) were used as positive controls. Among the monoynoic fatty acids, the
acid 2-hexadecynoic acid exhibited the best minimum inhibitory (MIC) values against
fluconazole resistant C. albicans ATCC 14053 and ATCC 60193 strains with MIC values
between 9.4 and 100 μM, respectively. However, as we have previously reported (8), 6-
nonadecynoic acid showed the best MIC values (<4.3 μM) against C. neoformans ATCC
66031, but it was not very effective against the fluconazole resistant C. albicans strains studied
herein (8). Therefore, introduction of a triple bond at either C-2 or C-6 in the alkyl chain was
effective in increasing the fungitoxicity of the fatty acid. However, a triple bond at either C-5
or C-9 in the alkyl chain was not particularly effective in increasing the fungitoxicity of the
fatty acids.
Among the studied diynoic fatty acids, 2,6-hexadecadiynoic acid (3a) displayed the best MIC
values against both the fluconazole resistant C. albicans ATCC 14053 and ATCC 60193 strains
with MIC values of 11.5 μM. However, 2,6-nonadecadiynoic acid (3c) displayed the best MIC
values (< 5.0 μM) among the diynoic acids against C. neoformans ATCC 66031, but it
displayed modest activity against the studied fluconazole resistant C. albicans strains with MIC
values between 20 and 80 μM (Table 1). A comparison of the bioactivity of 3a with that of the
2-hexadecynoic acid reveals that introduction of a second triple bond at C-6 increases the
fungitoxicity of the acid towards C. albicans ATCC 60193 (MIC = 11.5 μM) approximately
9 fold compared to 2-hexadecynoic acid (MIC = 100 μM). Therefore, the diynoic acid 3a has
the potential of displaying a broader antifungal profile than the parent 2-hexadecynoic acid.
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The acid 2,9-hexadecadiynoic acid (3b) was also studied and it was not particularly effective
against the fluconazole resistant C. albicans strains studied herein, but it displayed
fungitoxicity against C. neoformans ATCC 66031 with a MIC of < 5.8 μM. A comparison of
the bioactivity of 3b with that of the 9-hexadecynoic acid reveals that introduction of a second
triple bond at C-2 increases the fungitoxicity of the parent 9-hexadecynoic acid against the
three fungal strains studied, but the bioactivity of 3b was still poor as compared to that of either
3a or 3c.
In order to determine the selectivity of the 2,6-hexadecadiynoic acid (3a) towards fungi
(eukaryotic pathogens) vs. bacteria we chose to explore the antimycobacterial activity of both
3a and the 2-hexadecynoic acid towards Mycobacterium tuberculosis H37Rv following a
procedure previously described (16). We decided on M. tuberculosis since there is a recent
literature report indicating that the 2-hexadecynoic acid can be toxic (MIC’s ~ 10–20 μM in
Sauton’s medium) to mycobacteria by the accumulation of two metabolites, i.e., the 3-
ketohexadecanoic acid, which blocks fatty acid biosynthesis, and 3-hexadecynoic acid, an
inhibitor of fatty acid β-oxidation (17). The 2-hexadecynoic acid, therefore, can inhibit mycolic
acid biosynthesis, fatty acid biosynthesis, and fatty acid degradation (β-oxidation) pathways
of importance for mycobacteria (17).
Our antimycobacterial results are shown in Table 2. Two assays were used to study the
antimycobacterial activity of the acetylenic fatty acids, i.e., the microplate alamar blue assay
(MABA) and the low oxygen recovery assay (LORA). The MABA is the “normal” MIC
determination against replicating M. tuberculosis under aerobic conditions for 8 days. On the
other hand, the LORA utilizes M. tuberculosis under anaerobic non-replicating conditions for
11 days. As can be seen from Table 2, both acetylenic fatty acids displayed similar MIC’s of
around 140–145 μM (in Middlebrook 7H12 medium) against M. tuberculosis using the MABA
assay, but also both acids were not inhibitory to non-replicating and persistent M.
tuberculosis, as determined by the LORA assay (16). From these experiments we can conclude
that the additional Δ6 triple bond in 3a does not help in increasing its antimycobacterial activity
as compared to the 2-hexadecynoic acid, a fact that supports its postulated mechanism of action
(17). However, it is evident that acid 3a is a better antifungal agent than an antimycobacterial
agent for its specificity towards fungal cells, since the additional Δ6 triple bond in 3a makes
a difference in the antifungal activity.
With respect to the toxicity of the 2-alkynoic acids it was recently demonstrated that 2-alkynoic
acids could be used specifically against bacteria without toxicity to their host due to the fact
that the FASI complex in microsomal systems is not inhibited by the 2-alkynoic acids (17). In
addition, it was previously reported that despite the fact that the 2-hexadecynoic acid inhibits
the growth of HeLa cells, the simultaneous addition of palmitic acid to the culture medium
reverses the growth inhibition observed in HeLa cells, thus implying that toxicity would not
occur in animals consuming a normal diet (3).
Further experiments are required to determine the mechanism of antifungal activities by these
novel 2,6-diynoic FA. One possible mechanism of action for the 2,6-diynoic FA is
isomerization to a 2,3-allene (as the CoA derivative) and subsequent inhibition of the
biosynthesis of the fungal fatty acids as shown for the 2-hexadecynoic acid in intact animals
(4). Likewise, also analogous to the suspected mechanism of action for the 6-nonadecynoic
acid, the 2,6-diynoic FA could also inhibit sphingolipid biosynthesis in these fungi (7). Both
mechanisms of lipid biosynthesis inhibition could also be operative, thus explaining the
enhanced activity of 3a. Compound 3a has the potential for further evaluation in topical
formulations for the treatment of fungal infections, as antifungal in wound dressings, or as a
preservative in skin and hair care products.
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TABLE 1
Antifungal activity (MIC values, μM) against Candida albicans (SDB) and Cryptococcus neoformans (SDB) at
35–37°C after 24–48ha
Compound MIC (μM)
C. albicans ATCC 14053 C. albicans ATCC 60193 C. neoformans ATCC 66031
2-Hexadecynoic 9.4 100.3 <6.3
5-Hexadecynoic 7845 10460 61.3
9-Hexadecynoic 8260 11014 10.8
6-Nonadecynoic 6672 8896 <4.3
2,6-Hexadecadiynoic (3a) 11.5 11.5 <5.7
2,9-Hexadecadiynoic (3b) 4469 2235 <5.8
2,6-Nonadecadiynoic (3c) 20.0 80.2 <5.0
FLC >2000 >1000 <0.9
AMB <0.3 <0.3 <0.3
DMSO >5000 >5000 >5000
a
The results are the average of three separate experiments.
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TABLE 2
Minimum Inhibitory Concentrations (MIC values, μM) of 2,6-Hexadecadiynoic acid (3a) and 2-Hexadecynoic
acid Against Mycobacterium tuberculosis H37Rva
Compound MIC (μM)
MABA LORA
2,6-Hexadecadiynoic (3a) 145 >300
2-Hexadecynoic 141 >300
Rifampin 0.08 1.5
a
MABA, microplate alamar blue assay; LORA, low oxygen recovery assay.
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